Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:eltrombopag
|
| gptkbp:approvalYear |
2008
|
| gptkbp:ATCCode |
gptkb:B02BX05
|
| gptkbp:brand |
gptkb:Promacta
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:form |
gptkb:tablet
oral suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
Revolade
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
thrombopoietin receptor agonist
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache increased liver enzymes |
| gptkbp:usedFor |
chronic hepatitis C-associated thrombocytopenia
chronic immune thrombocytopenia severe aplastic anemia |
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|